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PharmacoeconomicsAn economic model evaluated the costs and outcomes of adjunctive clobazam therapy for Lennox–Gastaut syn-
drome (LGS) compared with adjunctive lamotrigine, ruﬁnamide, and topiramate. Clinical data were used to es-
timate baseline frequency and the percentage of drop-seizure reductions over 3 months (all comparators) and
2 years (ruﬁnamide). Claims data from a large US health care plan were employed to estimate costs. After
3 months, 21.5% of those receiving clobazam were drop-seizure–free. Over a 3-month horizon, clobazam was
more effective and less expensive than comparators, with the assumption that N0.77% of drop seizures required
medical care. Below this threshold, topiramate was less costly than clobazam. With the base-case assumption
that 2.3% of drop seizures were medically attended, costs for patients receiving clobazam totaled $30,147 versus
$34,223–$35,378 for comparators. Clobazam was more efﬁcacious and less costly than ruﬁnamide over a 2-year
horizon. The percentage of medically attended drop seizures was a driver of results. Clobazam treatmentmay be
cost-saving.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Lennox–Gastaut syndrome (LGS) is a debilitating form of childhood
epilepsy. The onset of LGS typically occurs between ages 1 and 7, and
LGS is estimated to account for up to 10% of childhood epilepsies [1,2].
Though no speciﬁc characteristics are diagnostic of LGS, it is associated
with frequent tonic or atonic falls (“drop attacks”) and cognitive impair-
ment [3]. Patientswith LGS have an increased risk ofmortality [4,5], and
nearly half of all patients with LGS experience sudden drop attacks,
which can lead to serious physical injury [1].
Lennox–Gastaut syndrome has considerable economic impact.
Seizures attributed to LGS are often refractory to treatment and, therefore,
increase the likelihood of patient hospitalization. A resource utilization
study found that seizures accounted for 16.9% of hospital admissions in
2006 [6], with an estimated annual cost per patient of $4,553 [7].
A survey-based analysis found that annual USmedical costs were notably
greater for children with epilepsy than for children without epilepsy
($6,379 vs. $1,976, respectively, adjusted for 2004 prices) [8]. In another
survey-based analysis of adult patients, the annual cost of epilepsy wascomes Research Life Sciences,
MA 02142, USA. Fax: +1 617
ments).
nc. Open access under CC BY-NC-ND liprojected to be $12.5 billion, including both direct costs (e.g., medical
services, diagnostic procedures, emergency room visits) and indirect
costs (e.g., lost wages for caregivers), adjusted to 1995 prices [9].
Approximately 80% of these costs were attributed to patients who had
intractable seizures.
Four antiepileptic drugs (AEDs: felbamate, lamotrigine, topiramate,
and ruﬁnamide) had been approved by the US Food and Drug Adminis-
tration (FDA) for the treatment of LGS. Clobazam(Onﬁ) became theﬁfth
when it was approved in October 2011 as an adjunctive treatment for
seizures associated with LGS for patients 2 years and older. Although
information about the economic proﬁle of AEDs for the treatment of
LGS is limited, recent analyses have reported the cost effectiveness of
ruﬁnamide in the United Kingdom. Adjunctive therapywith ruﬁnamide
was more costly than topiramate and lamotrigine but resulted in re-
duced frequency of total seizures and drop attacks [10] and greater
quality-adjusted life-years (QALYs) [11]. Ruﬁnamide was cost-effective
at a £30,000 per QALY gained threshold (e.g., comparedwith topiramate
but not lamotrigine). With the approval of clobazam as an adjunctive
treatment for LGS in the United States, the current analysis was
conducted to estimate the short- and long-term cost effectiveness of
clobazam as adjunctive therapy for LGS from a US payer perspective.
2. Methods
A trial-based economic model was developed to evaluate the cost
effectiveness and outcomes of clobazam versus competitor AEDs in
the treatment of LGS over 3-month and 2-year time frames.cense.
Table 2
Decreases in drop-seizure frequency following treatment with clobazam or ruﬁnamide
over a 2-year horizon.
Patients per seizure decrease
category, %
Month
3 6 9 12 15 18 21 24
Clobazam [13]
b50% decrease 38% 30% 32% 31% 36% 40% 44% 47%
50–b75% decrease 14% 21% 13% 13% 13% 14% 8% 2%
75–b100% decrease 19% 22% 27% 27% 23% 19% 22% 24%
Drop-seizure freedom 29% 28% 27% 29% 28% 26% 27% 27%
Mean % decrease 62% 65% 64% 64% 60% 56% 54% 52%
Ruﬁnamide [17]
b50% decrease 72% 67% 63% 71% 67% 69% 70% 71%
50–b75% decrease 7% 8% 9% 7% 8% 8% 8% 7%
75–b100% decrease 16% 18% 20% 16% 18% 17% 17% 16%
Drop-seizure freedom 6% 7% 7% 6% 6% 6% 6% 6%
Mean % decrease 42% 42% 43% 37% 38% 35% 34% 33%
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The model patient population comprised individuals with LGS
with characteristics similar to patients who had enrolled in the pivotal
study OV-1012 (also known as the CONTAIN trial) [12]. Key patient
characteristics included the following: 1) an LGS diagnosis, 2) 2 to
54 years of age with LGS onset before 11 years of age, 3) ≥2 drop sei-
zures per week, and 4) treatment with 1–3 concomitant AEDs.
2.2. Model overview and structure
At model initiation, patients were assumed to have had the same av-
erage number of drop seizures permonth as patients in clobazam clinical
trials at baseline, depending on the model time horizon: 128 drop sei-
zures/month for the 3-month horizon (CONTAIN) [12] and 132 drop sei-
zures/month for the 2-year horizon (OV-1004 clobazam open-label
extension [OLE] trial) [13]. Model assumptions were that patients had
the midpoint number of drop seizures in their seizure-reduction catego-
ries and that change in drop seizureswas linear between time points. The
average cost per drop seizure was multiplied by the number of drop
seizures occurring each month. Utility values were assigned based on
drop-seizure reduction category each month. The model assumed a
target clobazam dosage of 1.0 mg/kg/day for both the 3-month and
2-year time frame analyses.
After short-term treatment in the 3-month model, patients were
classiﬁed by their percentage decreases in drop-seizure frequency from
baseline (i.e., 128/month): 0%–b50%, 50%–b100%, and 100% (seizure-
free). Model comparators for the 3-month analysis included ruﬁnamide
(maximum dosage of 45 mg/kg/day), topiramate (target dosage of
6 mg/kg/day), and lamotrigine (maximum dosage of 5 mg/kg/day for
patients also receiving valproate; 15 mg/kg/day for patients not receiv-
ing valproate). Since no head-to-head comparison trials of these AEDs
have been reported, efﬁcacy estimates were adjusted for study differ-
ences using an indirect comparison of relative efﬁcacy versus a common
comparator (Table 1) [12,14–16]. Deﬁnitions of drop seizures differed
slightly between trials (e.g., ruﬁnamide and topiramate trials: drop sei-
zures included tonic–atonic seizures; lamotrigine and clobazam trials:
drop seizures included atonic, tonic, and myoclonic seizures that
resulted in falls).
After long-term treatment in the 2-yearmodel, patients were classi-
ﬁed by their percentage decreases in drop-seizure frequency from base-
line (i.e., 132/month): 0%–b50%, 50%–b75%, 75%–b100%, and 100%
(seizure-free). Over 2 years, 17.9% of patients receiving clobazam and
57.3% of patients receiving ruﬁnamide discontinued treatment. Patients
who discontinued at each time point were assumed to have returned to
their baseline drop-seizure rates. The model comparator for the 2-year
analysis was ruﬁnamide (maximum dosage of 45 mg/kg/day).
Efﬁcacy estimates for the decrease in drop seizures over 24 months
were derived from open-label studies of clobazam [13] and ruﬁnamide
[17] (Table 2). It should be noted that the percentage of ruﬁnamide pa-
tients in eachdrop-seizure reduction categorywas reported at 36 months
only. Interim efﬁcacy outcomeswere calculated using the fraction of the
36-month median reduction that had been achieved at each 3-month
time point. The fractions of the ﬁnal percentage reduction at each
time point were then multiplied by the percentage of patients in each
drop-seizure reduction category (50%–b75%, 75%–b100%, and 100%)Table 1
Decreases in drop-seizure frequency at 3 months by AED comparator.a
Patients per seizure decrease
category at 3 months, %
Clobazam
[12]
Ruﬁnamide
[14]
Topiramate
[16]
Lamotrigine
[15]
b50% decrease 32% 50% 59% 63%
50–b100% decrease 47% 45% 37% 37%
Drop-seizure freedom 21% 4% 3% 0%
Mean % decrease 64% 51% 46% 44%
a Indirect comparisons were used to adjust estimates.at the end of the trial to obtain the number of patients in each reduction
category every 3 months.
2.3. Cost parameters
Mean health care costs for medically attended seizures were identi-
ﬁed from a retrospective claims database analysis of patients with LGS
via administrative claims data from a large managed health care plan
(January 2007 to September 2010). An algorithm, developed in consul-
tationwith a pediatric neurologist (Dr. Deborah Lee, Lundbeck LLC), was
used to identify patients with LGS in the claims database and the cost of
seizure-attributable events (see Appendix A), which was estimated to
be $5,501 in 2013 US dollars [18]. Based on estimates from the literature
and the claims database analysis [10,18], it was assumed that 0.5% of
drop attacks resulted in hospitalization, representing 21.5% of all sei-
zures necessitating any medical costs (e.g., inpatient, outpatient, emer-
gency room services). However, this analysis also sought to consider
drop attacks treated in the clinical setting, as well as those treated in
the hospital setting. Therefore, with the algorithm and these assump-
tions, 2.3% of drop seizures were assumed to have been medically
attended.
Daily drug costs (based on 2013 prices) were calculated by ap-
plying the average dosages received in clinical trials (titration and
maintenance periods) — $22.41 for clobazam, $31.69 for ruﬁnamide,
$0.12 for topiramate, and $0.12 for lamotrigine — to the 2013
wholesale acquisition costs (WACs) [19].
2.4. Utility weights
For estimation of the number of QALYs associated with each treat-
ment, utility weights (a value that quantiﬁes health-related quality of
life in each health state, ranging from 0 [death] to 1 [perfect health])
were assigned to the drop-seizure reduction categories used in the
model. Utility estimates were obtained from a published study of cost
effectiveness of ruﬁnamide in the treatment of LGS (Table 3) [20]. The
study did not report the utility weight associated with 100% reduction.
As a conservative estimate, the 100% reduction group was assumed to
have had the same utility weight as the 75%–b100% seizure-reduction
group.Table 3
Utility weights by decrease in drop-seizure frequency category.
Category by decrease in drop-seizure frequency Utility [20]
Uncontrolled (0% decrease) 0.393
b50% decrease 0.461
50–b75% decrease 0.605
75–b100% decrease 0.699
Drop-seizure freedom (100% decrease) 0.699a
a Assumption.
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Costs and disutility of adverse events were not considered in the
model. The most common adverse effects reported during the clinical
trials (e.g., somnolence, vomiting, diarrhea, and fever) were considered
to be brief and not associated with a sustained decrease in quality of life
or medical costs.2.6. Model outputs and analyses
The model produced estimates of the total number of QALYs, num-
ber of drop seizures, the percentage of patients who achieved drop-
seizure freedom, and total costs. To calculate quality-adjusted life-
years, the percentage of the sample in each drop-seizure reduction
category each month was multiplied by the utility value associated
with the category and summed over the model horizon.2.6.1. Cost-effectiveness analysis
The cost effectiveness of clobazamwasmeasured using incremental
cost-effectiveness ratios (ICERs). These ICERs were estimated by rank-
ordering treatment strategies by increasing cost and comparing more
costly strategies with less costly strategies by dividing the additional
cost by the additional beneﬁt. A more costly strategy that provided no
additional beneﬁt was said to be “dominated.” Cost effectiveness was
expressed as cost per QALY gained, cost per drop seizure avoided, and
cost per drop-seizure–free patient.2.6.2. Deterministic sensitivity analyses
Deterministic (i.e., one-way) sensitivity analyses were performed
to assess the sensitivity of the cost-effectiveness analysis results to
changes in the values of input parameters. To perform these analy-
ses, we varied each parameter one at a time over the 95% conﬁdence
interval of the base-case values.When 95% conﬁdence intervals were
not available, parameters were varied by ±25% of the base-case
values.2.6.3. Probabilistic sensitivity analysis
A second-order probabilistic Monte Carlo sensitivity analysis
assessed uncertainty around the following base-case parameter values:
transition probabilities, treatment-related adverse events, utilities, and
treatment costs. Each parameterwas characterized by probability distri-
butions around their midpoint estimates. A random number generator
was used to “draw” values from each distribution to generate estimates
of cost effectiveness for each treatment strategy. This process was
repeated 1000 times, and the incremental results are presented
graphically. The Monte Carlo simulation estimated the likelihood
that clobazam was the dominant strategy.Fig. 1.Mean numbers of drop seizures per patient for clobazam and AED comparators over
(A) 3-month and (B) 2-year horizons.2.6.4. Additional sensitivity and alternative scenario analyses
When underlying model assumptions were uncertain, additional
sensitivity and alternative scenario analyses were conducted to test
the impact of alternative plausible assumptions. Analysis 1 presented
model results for a range of values for the assumption of the percentage
of seizures requiring medical attention. First, we calculated the param-
eter value at which the clobazam regimen was no longer the dominant
regimen. Next, for all values below the threshold, we calculated ICERs
comparing clobazam to the less costly regimen. In Analysis 2, an alterna-
tive scenario was performed in which discontinuers were assumed to
have maintained seizure control and retained their average percentage
decreases in drop seizures for the remaining horizon in the 2-year
model.3. Results
3.1. Base case: 3-month model
The adjusted percentage decreases of drop seizures per patient over
3 months for clobazam, ruﬁnamide, topiramate, and lamotrigine were
64%, 51%, 46%, and 44%, respectively. The mean numbers of drop sei-
zures per patient over 3 months are shown in Fig. 1A. Per-patient
drop-seizure costs were 93.3%, 91.9%, 99.9%, and 99.9% of the total treat-
ment costs for the clobazam, ruﬁnamide, topiramate, and lamotrigine
groups, respectively (Table 4). Themodel suggests that, over 3 months,
patientswho received clobazamexperienced fewer drop-seizure events
than thosewho received AED comparators (clobazam, 220; ruﬁnamide,
254; topiramate, 267; lamotrigine, 273), resulting in greater quality-
adjusted life-years gained. Moreover, 21.5% of patients who received
clobazam were free of drop seizures, compared with b5% for the AED
comparators. Clobazam dominated all comparators (i.e., it was less
expensive and more effective) in QALYs gained, decreases in drop-
seizure events, and percentage of patients who had attained drop-
seizure freedom over the 3-month horizon (Table 5).3.2. Base case: 2-year model
Over 2 years, patients receiving clobazam had a 53% reduction in
drop seizures, compared with a 33% reduction for patients receiving
ruﬁnamide (Fig. 1B). The total per-patient drug and drop-seizure costs
were $177,068 for patients receiving clobazam and $265,814 for pa-
tients receiving ruﬁnamide (Table 4). Cost of treating drop seizures
comprised 92.1% and 94.0% of total costs in clobazam and ruﬁnamide
arms, respectively. The model suggests that patients who received
clobazam experienced fewer drop seizures compared with patients
who received ruﬁnamide (1,312 drop seizures vs. 2,010 drop seizures,
respectively). Drop-seizure freedom was achieved by 26.7% of patients
who received clobazam versus 5.7% of those who received ruﬁnamide
(Table 5). Clobazam dominated ruﬁnamide based on QALYs gained,
Table 4
Base-case analysis: costs for clobazam and AED comparators (3-month and 2-year horizons).
Treatment Drop-seizure costs Drug costs Total costs
3-month horizon
Clobazam $28,130 $2,017 $30,147
Ruﬁnamide $32,526 $2,852 $35,378
Topiramate $34,212 $11 $34,223
Lamotrigine $34,960 $11 $34,970
2-year horizon
Clobazam $163,015 $14,053 $177,068
Ruﬁnamide $249,768 $16,046 $265,814
Fig. 2. Probabilistic sensitivity analysis of the (A) 3-month and (B) 2-year models.
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tients over a 2-year horizon.
3.3. Deterministic sensitivity analysis
When model parameters were varied one at a time through a range
of values, clobazam remained the dominant strategy (i.e., more
effective and less expensive) versus comparators in all scenarios
over the 3-month and 2-year time horizons.
3.4. Probabilistic sensitivity analysis
Incremental costs and outcomes of clobazam compared with
ruﬁnamide over the 3-month and 2-year time horizons showed that
clobazam was dominant in 100% of iterations (Figs. 2A and B).
3.5. Alternative scenarios
3.5.1. Scenario-1 analysis
Over the 3-month horizon, clobazamwas dominant for all values of
the percentage of seizures medically attended that were greater than
0.77%. Below this threshold, topiramate was less costly than clobazam.
ICERs comparing clobazamwith topiramate ranged fromapproximately
$2,300 per QALY gained, with an assumption that 0.76% of seizures re-
quire medical care, to $196,200 per QALY gained, with an assumption
that 0.05% of drop seizures require medical care. With the assumption
that 0.5% of seizures require medical care (the percentage of seizures
resulting in hospitalization reported in Verdian et al. [11]), clobazam
cost approximately $73,300 per QALY gained (Table 6). Over the 2-
year time horizon, clobazamwas dominant for all values of the percent-
age of seizures medically attended.
3.5.2. Scenario-2 analysis (clobazam vs. ruﬁnamide)
With the assumption that discontinuers retained their average
percentage drop-seizure decreases for the remaining horizon over the
2-year time frame, clobazam dominated ruﬁnamide as the latter was
both more expensive and less effective (Table 7).Table 5
Base-case analysis: costs, QALYs, and drop-seizure events for clobazam and AED comparators (
Treatment Cost/patient QALYs Drop-seizure
events
Proportion of
drop-seizure–f
patients
3-month horizon
Clobazam $30,147 0.129 219.5 0.215
Topiramate $34,223 0.120 266.9 0.031
Lamotrigine $34,970 0.119 272.7 0
Ruﬁnamide $35,378 0.122 253.8 0.044
2-year horizon
Clobazam $177,068 1.127 1,312 0.267
Ruﬁnamide $265,814 0.986 2,010 0.057
AED = antiepileptic drug; QALYs = quality-adjusted life-years.4. Discussion
In this study, costs andoutcomes associatedwith adjunctive clobazam
treatment in patients with LGS were compared with adjunctive treat-
ment with ruﬁnamide, topiramate, and lamotrigine over a 3-month
horizon and with ruﬁnamide over a 2-year horizon. The time horizons
were based on the availability of trial-based, short- and long-term
data. In base-case analyses, clobazam was more efﬁcacious and less ex-
pensive (i.e., greater drop-seizure reduction and number of QALYs
gained) than the comparator AEDs over both time horizons. Results
from deterministic sensitivity analyses revealed that the base-case pa-
rameter estimates were robust to reasonable variations across the 95%
conﬁdence interval range. Clobazam was also the dominant treatment
strategy in 100% of the iterations of the probabilistic sensitivity analysis.
Overall, patients treated with comparators had greater medical costs
than patients treated with clobazam, and this difference was driven
by reductions in medically attended drop seizures in patients treated
with clobazam.
The estimate for the percentage of medically attended drop seizures
(2.3%) could not be identiﬁed directly from the literature or database
analysis but was derived from the results of a survey of physicians in
the United Kingdom of the percentage of seizures that required hospi-
talization [10] and a US-based retrospective claims database analysis
[18]. The survey encompassed all types of epilepsy andwas not targeted
solely or speciﬁcally at a catastrophic epilepsy syndrome such as LGS.
Unlike the Verdian et al. analysis, which considered only seizures3-month and 2-year horizons).
ree
Cost/QALY gained Cost/drop seizure
avoided
Cost/drop-seizure–free
patient
Reference Reference Reference
Dominated Dominated Dominated
Dominated Dominated Dominated
Dominated Dominated Dominated
Reference Reference Reference
Dominated Dominated Dominated
Table 6
Alternative Scenario-1 analysis: costs, QALYs, and drop-seizure events for clobazam and AED comparators (3-month and 2-year horizons).a
Treatment Cost/patient QALYs Drop-seizure
events
Proportion of
drop-seizure–free
patients
Cost/QALY gained Cost/drop seizure
avoided
Cost/drop-seizure–free
patient
3-month horizon
Topiramate $7,353 0.120 266.9 0.031 Reference Reference Reference
Lamotrigine $7,513 0.119 272.7 0.000 Dominated Dominated Dominated
Clobazam $8,054 0.129 219 0.215 $73,324 $15 $3,813
Ruﬁnamide $9,832 0.122 254 0.044 Dominated Dominated Dominated
2-year horizon
Clobazam $42,776 1.127 1312 0.267 Reference Reference Reference
Ruﬁnamide $65,929 0.986 2010 0.057 Dominated Dominated Dominated
AED = antiepileptic drug; QALYs = quality-adjusted life-years.
a Alternative Scenario 1 assumed that 0.5% of drop seizures were medically attended (vs. 2.3% in the base case).
188 K.M. Clements et al. / Epilepsy & Behavior 29 (2013) 184–189attended in the hospital setting, we considered a percentage that would
reﬂect seizures treated in both the hospital and clinical settings. The
claims analysis was also used to estimate medical costs associated with
each seizure [10,18]. Interpretation of the claims analysis is subject to
the following limitations: 1) An ICD-9 code speciﬁc to the LGS form of
epilepsy does not exist, therefore an algorithm was used to identify the
patient population (algorithm has not been validated); 2) The study
was conducted in a managed care population and may not be indicative
of patients in a non-managed care setting; 3) Although claims are
excellent for understanding patterns of health care utilization, they are
subject to possible coding errors, such as coding for the purpose of
“ruling out” rather than actual disease coding and undercoding; and
4) Certain clinical and disease-speciﬁc parameters that could have an
effect on study outcomes are not readily available in claims data.
Given the uncertainty in the estimate of medically attended drop
seizures, we performed additional sensitivity analyses to evaluate the
results, following a range of assumptions. Results demonstrated that
over a 3-month horizon, clobazam was still the dominant regimen at
all values greater than 0.77%. Moreover, clobazam remained dominant
when compared with ruﬁnamide in the 2-year model at all values. In
addition, our alternative scenario and sensitivity analyses were broad
enough to encompass the percentage of medically attenuated seizures
reported in the hospital setting in the Verdian et al. analysis (0.5%) [10].
When data were not available, the following assumptions in the
base-case analysis were used to provide estimates. Patients were as-
sumed to have had the midpoint number of drop seizures in each
drop-seizure category and a linear change in drop seizures during
each 3-month interval for which data were reported. In addition,
the percentage of patients achieving each drop-seizure category at
each 3-month interval was not reported in the ruﬁnamide open-label
study [17], and, therefore, the percentage of patients reaching each
drop-seizure category was assumed to have been proportional to the
median seizure reduction at that time point.
In the base-case analysis, it was also assumed that patients who
discontinued treatment returned to their baseline drop-seizure rates. A
second alternative analysis assumed that patients whohad discontinued
treatment maintained seizure control. The results from the second
alternative analysis did not alter the conclusion that clobazam was
the dominant treatment.Table 7
Alternative Scenario-2 analysis: costs, QALYs, and drop-seizure events for clobazam and ruﬁna
Treatment Cost/patient QALYs Drop-seizure
events
Proportion of
drop-seizure–f
patients
Clobazam $164,421 1.144 1206 0.267
Ruﬁnamide $247,083 1.012 1853 0.057
QALYs = quality-adjusted life-years.
a Alternative Scenario 2 assumed that patients who had discontinued treatment maintained
discontinuation).Publications describing cost-effectiveness evaluations of AEDs in a
patient population with LGS are limited [10,11,21]. In the only publica-
tion presenting a cost–utility analysis, Verdian et al. estimated that
ruﬁnamide costs £20,538 and £154,831 per QALY gained compared
with topiramate and lamotrigine, respectively, over 3 years in patients
with LGS in the UK [11]. Our study estimated that clobazam was domi-
nant comparedwith topiramate and lamotrigine, as well as ruﬁnamide.
The differences between our study and the Verdian study were as fol-
lows: 1) The lack of published long-term efﬁcacy data for topiramate
and lamotrigine limited our study to a 3-month horizon to evaluate
cost effectiveness of clobazam relative to all AED comparators. If the
long-term efﬁcacy of topiramate and lamotrigine followed the same
pattern as clobazam and ruﬁnamide, clobazam would have remained
dominant relative to these two drugs over the long term; and 2) In
their study, Verdian et al. included only hospital costs, estimating that
0.5% of drop seizures led to hospitalization, whereas our study included
the costs of hospitalization and outpatient treatment. Althoughwe esti-
mated a greater cost per medically attended drop seizure, clobazam
dominated ruﬁnamide in the 2-year horizon.
Development of tolerance is a concern with the use of all AEDs, es-
pecially the long-term use of benzodiazepines. We could not account
for tolerance rates of topiramate, lamotrigine, and ruﬁnamide. Some of
the latest reports for clobazam do not necessarily agree. An inde-
pendent, retrospective chart review of 46 patients with LGS at the pedi-
atric neurology department of Asan Medical Center in Seoul, Korea
(2000–2009), reported tolerance for 12 of 25 patients (48%) [22]. How-
ever, several incongruences were reported in this and other analyses:
“Despite the development of tolerance, once complete remission had
been maintained, a signiﬁcant proportion of patients were found to re-
main seizure-free” [22,23]. Well-controlled data from 188 patients who
completed a 6-year open-label extension trial [24] found limited devel-
opment of tolerance, as suggested by sustained responses over time;
stable mean modal clobazam dosages over time; a substantial percent-
age (70%) of patients remaining in treatment through study completion,
with few discontinuing because of lack of efﬁcacy; and some patients
being able to reduce their concomitant AED therapies. Therefore, it is
difﬁcult to speculate on the roles, if any, of tolerance in these analyses.
In summary, this cost-effectiveness analysis suggests that treatment
with clobazam over the short- and long-term horizon is both less costlymide over a 2-year horizon.a
ree
Cost/QALY gained Cost/drop seizure
avoided
Cost/drop-seizure–free
patient
Reference Reference Reference
Dominated Dominated Dominated
seizure control (vs. the drop-seizure rate in the base case which returned to baseline after
189K.M. Clements et al. / Epilepsy & Behavior 29 (2013) 184–189and results in better efﬁcacy outcomes than lamotrigine, ruﬁnamide,
and topiramate. The results suggest that treatment with clobazam
leads to lower overall health care costs through a reduction in the num-
ber of medically attended drop seizures, especially in the long term.
Nevertheless, long-term data from patients prescribed clobazam in the
clinical setting will be critical to determining true cost effectiveness.
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